Follicular Lymphoma (FL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Follicular lymphoma, constituting 20-30% of all non-Hodgkin lymphomas, is the most prevalent subtype of low-grade (indolent) lymphoma. Its etiology remains unknown, ruling out infection as a causative factor and eliminating its potential for contagion. B-cell lymphoma, known as follicular lymphoma, is identified by tumor cells organized in a circular or clustered arrangement under microscopic examination. These anomalous follicles supplant the typical lymph node structure. Notably, over 90% of individuals with follicular lymphoma exhibit the CD20 protein on the surface of the malignant follicular cells, rendering them susceptible to certain treatment approaches. Prognosis and risk assessment for follicular lymphoma hinge on factors derived from the FLIP2 study, including Beta2 microglobulin exceeding the upper limit of normal, bone marrow involvement, hemoglobin levels below 12g/dL, the largest involved node's diameter exceeding 6 cm, and an age surpassing 60 years. The five-year progression-free survival rates based on these risk factors are as follows: Low risk (0 risk factors): 80%; Intermediate risk (1-2 risk factors): 51%; High risk (3-5 risk factors): 19%. The management of follicular lymphoma is contingent on the stage of the disease. Available treatment options encompass radiation therapy (RT), immunochemotherapy (Rituximab combined with chemotherapy), Bendamustine in conjunction with immunotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), immunochemotherapy combined with RT, CVP (cyclophosphamide, vincristine, and prednisolone), single-agent rituximab, and a strategy of monitoring until progression. The choice of treatment regimen is guided by the disease stage, the physician's recommendation, and the patient's preference.

·       The incidence rate of new cases of follicular lymphoma in the United States amounts to 2.5 cases per 100,000 men and women annually.

 

Thelansis’s “Follicular Lymphoma (FL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Follicular Lymphoma (FL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Follicular Lymphoma (FL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Follicular Lymphoma (FL) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Follicular Lymphoma (FL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Follicular Lymphoma (FL), Follicular Lymphoma (FL) market outlook, Follicular Lymphoma (FL) competitive landscape, Follicular Lymphoma (FL) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)